急性髓系白血病干细胞评估在多中心环境中的适用性与可重复性
该研究验证了单管流式细胞术检测急性髓系白血病(AML)白血病干细胞(LSC)在多中心间的可重复性。
要点
- 多中心检测的LSC百分比变异低于临床相关阈值
核心结论
- LSC检测具有高度可重复性,结合其诊断时的预后影响,可作为未来风险分层的良好标志物。
研究设计与样本
- 多中心验证研究,在欧洲和美国多个大型AML研究中心进行,验证单管流式细胞术LSC检测(含13个膜标记)。
主要发现
- 多中心检测引入LSC百分比变异,但低于临床相关阈值。
临床怎么用
- 该单管LSC检测可用于AML患者诊断时的LSC负荷评估,支持风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukaemic stem cells (LSC) have been experimentally defined as the leukaemia-propagating population and are thought to be the cellular reservoir of relapse in acute myeloid leukaemia (AML). Therefore, LSC measurements are warranted to facilitate accurate risk stratification. Previously, we published the composition of a one-tube flow cytometric assay, characterised by the presence of 13 important membrane markers for LSC detection. Here we present the validation experiments of the assay in several large AML research centres, both in Europe and the United States. Variability within instruments and sample processing showed high correlations between different instruments (Rpearson > 0·91, P < 0·001). Multi-centre testing introduced variation in reported LSC percentages but was found to be below the clinical relevant threshold. Clear gating protocols resulted in all laboratories being able to perform LSC assessment of the validation set. Participating centres were nearly unanimously able to distinguish LSChigh (>0·03% LSC) from LSClow (<0·03% LSC) despite inter-laboratory variation in reported LSC percentages. This study proves that the LSC assay is highly reproducible. These results together with the high prognostic impact of LSC load at diagnosis in AML patients render the one-tube LSC assessment a good marker for future risk classification.
引用
- Hanekamp D, Snel AN, Kelder A, et al. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. Br J Haematol. 2020. PMID: 32239670. doi:10.1111/bjh.16594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。